Nonprofit · EIN 46-0886344
TRANSCELERATE BIOPHARMA INC
Tax-exempt · WEST CONSHOHOCKEN, PA 19428
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| December 31, 2025 | 990 | $34,242,546 | $33,032,304 | $1,210,242 | $55,072,425 | $35,380,185 | $19,692,240 |
| December 31, 2024 | 990 | $38,595,799 | $31,739,939 | $6,855,860 | $55,325,009 | $36,830,722 | $18,494,287 |
Financial details: 990 for the year ended December 31, 2025
Revenue
- Contributions, gifts and grants
- $0
- Program service revenue
- $33,003,000
- Investment income
- $1,239,546
- Other revenue
- $0
Expenses
- Grants and similar amounts paid
- $0
- Compensation of officers, directors and key employees
- $1,940,738
- Other salaries and wages
- $7,729,478
- Salaries, compensation and benefits (total)
- $11,246,091
- Professional fundraising fees
- $0
- Legal fees
- $3,005,795
- Accounting fees
- $26,458
- Occupancy
- $364,676
- Travel
- $580,873
- Program services (functional)
- $22,040,051
- Management and general (functional)
- $10,992,253
Balance sheet and other
- Total assets, start of year
- $55,325,009
- Total assets, end of year
- $55,072,425
- Total liabilities, end of year
- $35,380,185
- Net assets, end of year
- $19,692,240
- Net assets without donor restrictions
- $19,692,240
- Gross receipts
- $34,242,546
- Employees
- 35
- Volunteers
- 28
- Year formed
- 2012
- State of legal domicile
- DE
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended December 31, 2025, highest compensation first.
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| JANICE CHANG | CEO Trustee or director, Officer | 40 | $1,174,019 | $53,270 |
| ALLISON CUFF SHIMOOKA | COO Officer | 40 | $657,690 | $59,759 |
| JENNIFER BURGESS | VP, GLOBAL COMM & ENGAG (THRU 7/2025) Highest-paid employee | 40 | $486,057 | $51,172 |
| CARA RINALDI | VP, PORTFOLIO MANAGEMENT Highest-paid employee | 40 | $448,212 | $59,095 |
| ANTHONY GARGES | HEAD OF FINANCE & ADMINISTRATION Highest-paid employee | 40 | $435,545 | $58,512 |
| ROBERT DICICCIO | VP, PORTFOLIO MANAGEMENT Highest-paid employee | 40 | $435,340 | $55,553 |
| JENEEN DONADEO | EXEC. PORTFOLIO DIRECTOR Highest-paid employee | 40 | $411,601 | $47,045 |
| ELIAV BARR | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| KAMRAN ANSARI | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| LIONEL BASCLES | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| DIETMAR BERGER | BOARD MEMBER (EFF 3/2025) Trustee or director | 0.5 | $0 | $0 |
| PHILLIPPA BROWN | BOARD MEMBER (EFF 4/2025) Trustee or director | 0.5 | $0 | $0 |
| SERBAN GHIORGHIU | BOARD MEMBER (EFF 8/2025) Trustee or director | 0.5 | $0 | $0 |
| RUCHIRA GLASER | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| LYKKE HINSCH GYLVIN | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
23 more people on this return
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| ELIZABETH VAN SANT HOFFMAN | BOARD MEMBER (EFF 4/2025) Trustee or director | 0.5 | $0 |
| NARIMON HONARPOUR | BOARD MEMBER Trustee or director | 0.5 | $0 |
| CHRISTOPH KOENEN | BOARD MEMBER Trustee or director | 0.5 | $0 |
| MARIA KOUTSOPOULOU | BOARD MEMBER Trustee or director | 0.5 | $0 |
| BARI KOWAL | BOARD MEMBER Trustee or director | 0.5 | $0 |
| FABIO LIEVANO | BOARD MEMBER Trustee or director | 0.5 | $0 |
| FIONA DU MONCEAU | BOARD MEMBER (EFF 3/2025) Trustee or director | 0.5 | $0 |
| MARIANNE OLHOLM | BOARD MEMBER (EFF 12/2025) Trustee or director | 0.5 | $0 |
| MICHELLE ROHRER | BOARD MEMBER Trustee or director | 0.5 | $0 |
| MOKASH SHARMA | BOARD MEMBER Trustee or director | 0.5 | $0 |
| TADAAKI TANIGUCHI | BOARD MEMBER Trustee or director | 0.5 | $0 |
| TAKEKI UEHARA | BOARD MEMBER (EFF 12/2025) Trustee or director | 0.5 | $0 |
| CHRIS CORSICO | BOARD MEMBER (THRU 3/2025) Trustee or director | 0.5 | $0 |
| CRISTIAN MASSACESI | BOARD MEMBER (THRU 8/2025) Trustee or director | 0.5 | $0 |
| ROBERT METCALF | BOARD MEMBER (THRU 3/2025) Trustee or director | 0.5 | $0 |
| MERDAD PARSEY | BOARD MEMBER (THRU 3/2025) Trustee or director | 0.5 | $0 |
| TOM SENDEROVITZ | BOARD MEMBER (THRU 10/2025) Trustee or director | 0.5 | $0 |
| BADHRI SRINIVASAN | BOARD MEMBER (THRU 1/2025) Trustee or director | 0.5 | $0 |
| TAKUKO YAMADA-SAWADA | BOARD MEMBER (THRU 12/2025) Trustee or director | 0.5 | $0 |
| IRIS LOEW-FRIEDRICH | BOARD MEMBER (THRU 3/2025) Trustee or director | 0.5 | $0 |
| JENNIFER SHELLER | TREASURER (EFF 8/2025) Officer | 0.5 | $0 |
| RAJA MANGIPUDY | CORPORATE SECRETARY (EFF 4/2025) Officer | 0.5 | $0 |
| ANDREW LEE | TREASURER (THRU 6/2025) Officer | 0.5 | $0 |
990 for the year ended December 31, 2024: 34 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| JANICE CHANG | CEO Trustee or director, Officer | 40 | $1,062,291 | $42,514 |
| ALLISON CUFF SHIMOOKA | COO Officer | 40 | $582,003 | $54,161 |
| JENNIFER A BURGESS | VP, GLOBAL COMMUNICATIONS & ENGAGEMENT Highest-paid employee | 40 | $461,236 | $44,362 |
| CARA L RINALDI | VP, PORTFOLIO MANAGEMENT Highest-paid employee | 40 | $417,189 | $53,497 |
| ROBERT DICICCO | VP, PORTFOLIO MANAGEMENT Highest-paid employee | 40 | $389,486 | $66,267 |
| ANTHONY GARGES | HEAD OF FINANCE & ADMINISTRATION Highest-paid employee | 40 | $397,818 | $47,267 |
| JENEEN DONADEO | EXEC. PORTFOLIO DIRECTOR Highest-paid employee | 40 | $395,823 | $33,953 |
| KATHRYN OWEN | CHAIR OF BOARD OF DIRECTORS Trustee or director | 0.5 | $0 | $0 |
| BADHRI SRINIVASAN | VICE CHAIR OF BOARD OF DIRECTOR Trustee or director | 0.5 | $0 | $0 |
| ELIAV BARR | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| DIETMAR BERGER | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| CHRIS CORSICO | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| ROB GOODWIN | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| LYKKE HINSCH GYLVIN | BOARD MEMBER (EFF 6/2024) Trustee or director | 0.5 | $0 | $0 |
| NARIMON HONARPOUR | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| CHRISTOPH KOENEN | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| MARIA KOUTSOPOULOU | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| BARI KOWAL | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| FABIO LIEVANO | BOARD MEMBER (EFF 11/2024) Trustee or director | 0.5 | $0 | $0 |
| IRIS LOEW-FRIEDRICH | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| CRISTIAN MASSACESI | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| ROBERT METCALF | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| MICHELLE ROHRER | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| MERDAD PARSEY | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| MOKASH SHARMA | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| TOM SENDEROVITZ | BOARD MEMBER (EFF 4/2024) Trustee or director | 0.5 | $0 | $0 |
| TADAAKI TANIGUCHI | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| TAKUKO YAMADA-SAWADA | BOARD MEMBER Trustee or director | 0.5 | $0 | $0 |
| ULI BROEDL | BOARD MEMBER (THRU 6/2024) Trustee or director | 0.5 | $0 | $0 |
| MARTIN HOLST LANGE | BOARD MEMBER (THRU 4/2024) Trustee or director | 0.5 | $0 | $0 |
| RAGAD ATTAR | BOARD MEMBER (EFF-5/24/ THRU-8/24) Trustee or director | 0.5 | $0 | $0 |
| ROOPAL THAKKAR | BOARD MEMBER (THRU 4/2024) Trustee or director | 0.5 | $0 | $0 |
| ANDREW LEE | TREASURER Officer | 0.5 | $0 | $0 |
| STEPHEN LIN | SECRETARY (THRU 11/2024) Officer | 0.5 | $0 | $0 |
Address and contacts
- Address (IRS master file)
- 300 CONSHOHOCKEN STATE ROAD, WEST CONSHOHOCKEN, PA 19428-3801
- In care of
- % GARRY NEIL
- Principal officer (990 for 2025)
- JANICE CHANG, 300 CONSHOHOCKEN STATE ROAD 420, WEST CONSHOHOCKEN, PA 19428
- Signed the 990
- JANICE CHANG, CEO
- Phone
- (484) 539-1230
- Return prepared by
- EISNER ADVISORY GROUP LLC
Mission
THE ORGANIZATION'S MISSION IS TO COLLABORATE ACROSS THE GLOBAL BIOPHARMACEUTICAL R&D COMMUNITY TO IDENTIFY, DESIGN AND FACILITATE IMPLEMENTATION OF SOLUTIONS DESIGNED TO DRIVE THE EFFICIENT, EFFECTIVE AND HIGH QUALITY DELIVERY OF NEW MEDICINES.
Program accomplishments
- IN 2025, TRANSCELERATE DELIVERED PRACTICAL SOLUTIONS TO SIMPLIFY TRIAL DESIGN AND EXECUTION, STRENGTHEN QUALITY, AND REDUCE BURDEN ACROSS THE R&D ECOSYSTEM. THE APPROACH COMBINED RAPID IMPROVEMENTS FOR IMMEDIATE IMPLEMENTATION WITH LONG-TERM SOLUTIONS TO HELP PROMISING THERAPIES REACH PATIENTS MORE QUICKLY AND SAFELY.THE ORGANIZATION LED 12 ACTIVE INITIATIVES IN 2025 AND LAUNCHED MORE THAN 60 TOOLS AND SOLUTIONS ACROSS THREE AREAS OF FOCUS:- TRANSFORMING CONNECTIVITY: REDEFINING HOW RESEARCH AND CARE INTERACT- INFORMATION SHARING AND REUSE: LEVERAGING EXISTING DATA FOR FASTER DEVELOPMENT- INNOVATIVE TRIAL DESIGN: PUTTING PATIENTS AT THE HEART OF CLINICAL TRIALS.HIGHLIGHTS OF 2025 PROGRESS:- DIGITAL DATA FLOW (DDF): SPONSORS CONTINUED TO ADOPT DDF WHILE GROWING INTEREST FROM SOLUTION PROVIDERS SHOWED THAT DIGITAL PROTOCOL INNOVATION IS MOVING FROM EARLY PILOT TO EVERYDAY PRACTICE.- ICH E6(R3) SUPPORT: FIFTEEN PRACTICAL TOOLS GAVE THE INDUSTRY WAYS TO ADAPT TO MUCH-ANTICIPATED NEW GUIDANCE ON GOOD CLINICAL PRACTICE EARNING WIDE MEDIA COVERAGE ALONG THE WAY.- CLINICAL DATA SHARING: USAGE OF TRANSCELERATE'S DATACELERATE PLATFORM MORE THAN DOUBLED, DEMONSTRATING THE GROWING IMPACT OF DATA REUSE TO REDUCE BURDEN AND IMPROVE TRIAL DESIGN.- PATIENT SAFETY REPORTING: A MANUSCRIPT IN A PROMINENT JOURNAL AND DIALOGUE WITH MULTIPLE HEALTH AUTHORITIES MARKED CRUCIAL FIRST STEPS TOWARD MODERNIZING INDIVIDUAL CASE SAFETY REPORTING. - EMBEDDED PRAGMATIC TRIALS: TRANSCELERATE PUBLISHED A NEW RESOURCE GUIDE AND IN COLLABORATION WITH THE FDA RELEASED A PUBLIC SUMMARY OF A JOINT EXERCISE TO IDENTIFY ACTIONABLE OPPORTUNITIES TO SCALE THE USE OF PRAGMATIC ELEMENTS.TRANSCELERATE HEALTH AUTHORITY DIALOGUE EXPANDED ACROSS FOUR CONTINENTS WITH CONTINUED FOCUS ON PRODUCTIVE COLLABORATION. THE ORGANIZATION ALSO PARTNERED WITH A VARIETY OF OUTSIDE ORGANIZATIONS, INCLUDING WITH THE TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT (CSDD) TO PUBLISH A BENCHMARKING STUDY ON PROTOCOL COMPLEXITY.- TRANSCELERATE GLOBAL REACH AND PRESENCE EXPANDED IN 2025. HIGHLIGHTS INCLUDED HOSTING 8 PUBLIC WEBINARS REACHING 7,000+ PROFESSIONALS, COVERAGE IN 50+ PUBLICATIONS, AND PRESENTATIONS AT MORE THAN 20 CONFERENCES ACROSS NORTH AMERICA, EUROPE, ASIA, AND SOUTH AMERICA.THE ORGANIZATION'S WORK IN 2025 WAS AND WILL CONTINUE TO BE ORIENTED AROUND A VISION OF SEAMLESS CONVERGENCE OF RESEARCH AND CARE, SO THAT TRIAL PARTICIPATION BECOMES A NATURAL PART OF HEALTHCARE PROCESSES.Expenses $22,040,051 · revenue $33,003,000
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | December 31, 2025 | May 15, 2026 | 990 on file |
| 2024 | December 31, 2024 | May 15, 2025 | 990 on file |
| 2023 | December 31, 2023 | May 15, 2024 | 990 on file |
IRS record
- EIN
- 46-0886344
- Tax-exempt status
- 501(c)(6): Business league or chamber of commerce
- Donations deductible
- No
- Exempt since
- 2014
- Accounting year ends
- December
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Medical research (H99)
- Assets (IRS master file)
- $55,072,425
- Income (IRS master file)
- $34,242,546
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | December 2025 | – | – | – | IRS |
| 990 | December 2024 | – | – | – | IRS |
| 990 | December 2023 | $34,168,812 | $32,521,149 | $48,107,662 | IRS |
| 990 | December 2022 | $33,600,302 | $34,262,372 | $48,482,660 | IRS |
| 990 | December 2021 | – | – | – | IRS |
| 990 | December 2020 | – | – | – | IRS |
| 990 | December 2019 | – | – | – | IRS |
| 990 | December 2018 | – | – | – | IRS |
990-N: the IRS publishes only the latest e-Postcard per organization; earlier years appear here as 990.tax collects the monthly files. 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS.
Questions about TRANSCELERATE BIOPHARMA INC
- What is the EIN of TRANSCELERATE BIOPHARMA INC?
- The employer identification number (EIN) of TRANSCELERATE BIOPHARMA INC is 46-0886344.
- Is TRANSCELERATE BIOPHARMA INC tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(6) since 2014.
- Are donations to TRANSCELERATE BIOPHARMA INC tax-deductible?
- No. The IRS master file says contributions to it are not deductible.
- Which annual return does TRANSCELERATE BIOPHARMA INC file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of TRANSCELERATE BIOPHARMA INC due?
- The return for tax year 2026 (the year ending December 31, 2026) is due May 17, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did TRANSCELERATE BIOPHARMA INC last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended December 2025.
- Who is the principal officer of TRANSCELERATE BIOPHARMA INC?
- The 990 for the year ended December 31, 2025 names JANICE CHANG.
- Who are the officers and directors of TRANSCELERATE BIOPHARMA INC?
- The 990 for the year ended December 31, 2025 lists 38 people; 7 received compensation from the organization, the highest $1,174,019 (JANICE CHANG, CEO).
- How much revenue does TRANSCELERATE BIOPHARMA INC have?
- On its 990 for the year ended December 31, 2025 it reported revenue of $34,242,546, expenses of $33,032,304 and total assets of $55,072,425 at year end.
Other nonprofits in WEST CONSHOHOCKEN
- CONSTRUCTION FINANCIAL MANAGEMENT ASSOCIATION EIN 23-2539799 · last filed 990-EZ for 2026
- JEWEL STAR FRANKLIN FAMILY FOUNDATION EIN 93-2230440 · last filed 990-N for 2025
- ENLIGHTENED WORLD FOUNDATION EIN 23-2830237 · last filed 990 for 2024
- LOUISE A HAVENS FOUNDATION FOR DIABETES RESEARCH AND TREATMENT EIN 25-6587514 · last filed 990-PF for 2025
- MAGUIRE FOUNDATION EIN 23-3057805 · last filed 990-PF for 2024
- WOLF CREEK CHARITABLE FOUNDATION EIN 83-0310959 · last filed 990-PF for 2024
- JOHN TEMPLETON FOUNDATION EIN 62-1322826 · last filed 990-PF for 2024
- CHRIS AND ELLEN MAGUIRE FOUNDATION EIN 88-1096232 · last filed 990-PF for 2025
All nonprofits in WEST CONSHOHOCKEN · Pennsylvania · Medical research